The stock boasts the one year return of 34.3%, in contrast to 16.4% for the S&P 500. This situation necessitates a ...

Hims & Hers Health (NYSE: HIMS) went public in January 2021 through a SPAC merger, positioning itself as a multi-specialty ...

Maple Tree Capital, an investment management company, released its Q3 2025 investor letter. A copy of the letter can be ...

Hims & Hers wants to launch its own weight loss program with GLP-1s like Ozempic. CEO Andrew Dudum worries about three challenges to the new market.

Mixed options sentiment in Hims and Hers Health (HIMS), with shares down 40c near $33.91. Options volume roughly in line with average with 56k ...

Hims & Hers compounded GLP-1 — the same ingredient as Ozempic — will be priced at $200 a month. Investors are loving the announcement.

Detailed price information for Hims & Hers Health Inc (HIMS-N) from The Globe and Mail including charting and trades.

A short squeeze occurs when a stock's price rises unexpectedly, forcing short sellers (who are now losing money) to ...

Hims & Hers Health (NYSE: HIMS), a telehealth platform, has recently announced its Q1 financial results, showing notable year-over-year growth. The company reported adjusted earnings per share of ...

Hims & Hers leads three healthcare IT stocks up over 20% in 2025, as digital care, remote monitoring and data platforms gain traction.

In recent years, we've seen a broader dialogue around the benefits of creating affordable, accessible health care for all—and whether or not it's actually achievable. While there's still plenty of ...